Evaluating Pharmaceuticals For Health Policy And Reimbursement Nick Freemantle by Nick Freemantle, Suzanne Hill 9780470994719, 9780727917843, 0470994711, 0727917846 instant download after payment.

So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders.

Chapters include

• Development of marketing authorisation procedures for pharmaceuticals


• Interpreting clinical evidence


• International pharmaceutical policy: health creation or wealth creation?


• Development of fourth hurdle policies around the world


• Economic modelling in drug reimbursement


• Priority setting in health care: matching decision criteria with policy objectives


• Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis


• Relationship between stakeholders: managing the war of words


• Medicine and the media: good information or misleading hype?


• How to promote quality use of cost-effective medicines


• Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable


• Pricing of pharmaceuticals


• Evaluating pharmaceuticals for health policy in low and middle income country settings.

Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.Content:
Chapter 1 Introduction (page 0): Nick Freemantle and Suzanne Hill
Chapter 2 Development of Marketing Authorisation Procedures for Pharmaceuticals (pages 3–23): Alar Irs, Truus Janse de Hoog and Lembit Rago
Chapter 3 Interpreting Clinical Evidence (pages 24–45): Nick Freemantle, Joanne Eastaugh, Melanie Calvert, Suzanne Hill and Jesse Berlin
Chapter 4 International Pharmaceutical Policy: Health Creation or Wealth Creation? (pages 46–66): Karen Bloor and Alan Maynard
Chapter 5 Development of Fourth Hurdle Policies Around the World (pages 67–87): Rod S Taylor, Mike F Drummond, Glen Salkeld and Sean D Sullivan
Chapter 6 Economic Modelling in Drug Reimbursement (pages 88–104): Glenn Salkeld, Nick Freemantle and Bernie O'Brien
Chapter 7 Priority Setting in Health Care:Matching Decision Criteria with Policy Objectives (pages 105–120): Gina Brinsmead and Alan Williams
Chapter 8 Tensions in Licensing and Reimbursement Decisions: The Case of Riluzole for Amytrophic Lateral Sclerosis (pages 121–138): Stirling Bryan, Josie Sandercock, Pelham Barton and Amanda Burls
Chapter 9 Relationships Between Stakeholders: Managing the War of Words (pages 139–156): Suzanne Hill and Kees de Joncheere
Chapter 10 Medicine and the Media: Good Information or Misleading Hype? (pages 157–173): Moynihan Ray, Lisa M Schwartz and Steven Woloshin
Chapter 11 How to Promote Quality Use of Cost?Effective Medicines (pages 174–189): Hans Hogerzeil and Kathleen Holloway
Chapter 12 Using Economic Evaluation to Inform Health Policy and Reimbursement: Making it Happen and Making it Sustainable (pages 190–207): Andrew Mitchell
Chapter 13 Pricing of Pharmaceuticals (pages 208–226): David Newby, Andrew Creese and Alan Stevens
Chapter 14 Evaluating Pharmaceuticals for Health Policy in Low and Middle Income Country Settings (pages 227–243): Andrew Creese, Anita Kotwani, Joseph Kutzin and Anban Pillay